Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 803-808, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alonsozana, G. L.
Right arrow Articles by Christenson, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alonsozana, G. L.
Right arrow Articles by Christenson, R. H.

Clinical Chemistry, Vol 42, 803-808, Copyright © 1996 by American Association for Clinical Chemistry

The case for cardiac troponin T: marker for effective risk stratification of patients with acute cardiac ischemia

GL Alonsozana and RH Christenson
Department of Pathology, University of Maryland School of Medicine, Baltimore, 21201, USA.

Availability of markers such as cardiac troponin T (cTnT) has brought new insights into ischemic heart disease (IHD). cTnT is a distinct protein that differs from other markers in biological function, molecular mass, and cytosolic pool. cTnT has been utilized for diagnosis of acute myocardial infarction (AMI) and risk stratification of patients with IHD. For AMI diagnosis, cTnT showed high sensitivity (94-100%) but generally lower specificity (46-99%), possibly because of increases in non-AMI patients with minor myocardial damage. Outcome studies have demonstrated that IHD patients with increased cTnT are at significantly greater risk for cardiac events; revascularization in patients with increased cTnT may improve outcome. Estimated costs for batched ES 300 cTnT results and for a cTnT rapid assay run "on demand" were $17.48 and $21.65, respectively. cTnT currently has no specific common procedure test code; expected reimbursement is $18.32 for the ES 300 and is not established for the rapid assay.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. H. Christenson and H. M. E. Azzazy
Biochemical markers of the acute coronary syndromes
Clin. Chem., August 1, 1998; 44(8): 1855 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. Coudrey
The Troponins
Arch Intern Med, June 8, 1998; 158(11): 1173 - 1180.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. H. Christenson, S.-H. Duh, L. K. Newby, E. M. Ohman, R. M. Califf, C. B. Granger, S. Peck, K. S. Pieper, P. W. Armstrong, H. A. Katus, et al.
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes
Clin. Chem., March 1, 1998; 44(3): 494 - 501.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.